This rare disease therapeutics specialist reported a notable insider sale amid a year of strong share price gains and ...
Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results